Apertura Gene Therapy has joined a Broad Institute-led consortium receiving an award of up to $34.5 million from the Advanced Research Projects Agency for Health to develop gene-editing treatments for rare pediatric neurological diseases. Apertura will contribute TfR1 CapX, its investigational central nervous system-targeted adeno-associated virus capsid, for delivery of base-editing and prime-editing programs within the Pediatric Epilepsies and Rare CNS Gene Editing Platform, known as PERC.
The funding is being awarded to the Broad Institute as the prime recipient rather than directly to Apertura. Apertura’s participation therefore represents inclusion in a publicly funded development platform and potential validation of its delivery technology, but it should not be interpreted as a $34.5 million financing for the private biotechnology company or as evidence that TfR1 CapX has demonstrated safety or therapeutic benefit in humans.
PERC will initially focus on alternating hemiplegia of childhood and Dravet syndrome, two severe genetic neurological disorders beginning in childhood. The broader objective is to create shared manufacturing processes, regulatory precedent, clinical infrastructure and patient-engagement systems that can be reused across multiple rare central nervous system diseases rather than rebuilding the development pathway separately for every mutation.
That platform ambition is the commercially and clinically important part of the announcement. Apertura is not simply supplying another viral vector to an isolated research project. Its capsid is being evaluated as one component of an integrated model intended to combine disease-specific editing instructions with reusable delivery, manufacturing and clinical-development capabilities.
Why does Apertura’s TfR1 CapX matter to the PERC gene-editing platform?
Delivering genetic medicines throughout the brain remains one of the central technical barriers in neurological gene therapy. The blood-brain barrier protects the central nervous system from circulating substances, but the same protective function limits the ability of systemically administered therapeutic vectors to reach sufficient numbers of neurons and other target cells.
TfR1 CapX is designed to address this obstacle by binding human transferrin receptor 1, which is expressed at the blood-brain barrier. Apertura says the capsid can be administered intravenously, cross the barrier and distribute genetic material across the brain and spinal cord. That approach could avoid neurosurgical administration or direct injection into cerebrospinal fluid, although the practical safety, dosing and distribution profile must still be established clinically.
The scientific foundation comes partly from work on BI-hTFR1, an earlier capsid engineered by researchers at the Broad Institute. A peer-reviewed study published in Science found that BI-hTFR1 crossed a human brain endothelial-cell model and produced approximately 40 to 50 times greater central nervous system reporter expression than AAV9 in mice engineered to carry the human transferrin receptor. The effect was specific to the human-receptor mouse model and was not observed in ordinary wild-type mice.
Those findings support the receptor-targeting concept, but they remain preclinical. Reporter expression in genetically modified mice does not establish safe or effective delivery in children, and the published study assessed the first-generation BI-hTFR1 vector rather than Apertura’s proprietary second-generation TfR1 CapX capsid. Apertura has described TfR1 CapX as providing improved central nervous system delivery, but the comparative evidence supporting that description has not yet been established through human clinical data.
PERC therefore gives Apertura an opportunity to test whether its vector can move beyond promising capsid engineering and become a repeatable delivery component for multiple therapeutic products. If different editing programs can use the same capsid while preserving sufficiently similar manufacturing, biodistribution and safety characteristics, the development burden for later rare-disease therapies could potentially be reduced.
What do the Dravet syndrome and AHC animal studies actually establish?
The consortium enters the program with meaningful preclinical gene-editing work already completed for its first two diseases. Alternating hemiplegia of childhood is commonly associated with pathogenic variants in ATP1A3 and can cause recurrent paralysis, seizures, movement abnormalities and developmental impairment. Dravet syndrome is most frequently caused by loss-of-function variants in SCN1A and is characterised by difficult-to-control seizures, cognitive impairment and elevated mortality risk.
In a 2025 Cell study, Broad Institute and collaborating researchers developed base-editing and prime-editing strategies for five ATP1A3 mutations associated with alternating hemiplegia of childhood. The investigators reported correction efficiencies ranging from 43% to 90% in experimental cell systems. AAV9-mediated prime editing in two mouse models produced up to 48% DNA correction and 73% messenger RNA correction in bulk brain cortex while improving movement, cognitive and episodic disease phenotypes and extending survival.
A separate 2026 study in Science Translational Medicine evaluated adenine base editing for an SCN1A mutation associated with Dravet syndrome. Using a dual-AAV9 delivery system, researchers reported 59% DNA editing and 97% messenger RNA editing in bulk neocortical tissue in treated neonatal mice. Treatment reduced spontaneous and temperature-induced seizures and was associated with improved short-term survival compared with vehicle-treated animals.
These studies provide a strong biological rationale for advancing the programs, but they do not demonstrate that PERC’s proposed therapeutic products will work in patients. The experiments were conducted in mouse models, and the reported therapeutic delivery relied on AAV9 rather than TfR1 CapX. Combining the editors with a different capsid creates a new development package whose potency, cellular distribution, dose requirements, manufacturing consistency and safety will need to be re-established.
That distinction is particularly important because a capsid cannot be assessed independently of the genetic cargo it carries. Changes to the editor, guide sequence, regulatory elements or vector configuration can alter expression, biodistribution and toxicity. The platform may allow certain information to be reused, but each disease-specific product will retain scientific and regulatory questions of its own.
Can shared infrastructure overcome the economics of ultra-rare pediatric brain diseases?
Developmental and epileptic encephalopathies collectively affect more than three million children worldwide and have been linked to mutations across more than 400 genes. A single pathogenic variant may occur in only a small number of patients, leaving conventional commercial drug-development models poorly suited to creating individual therapies for every genetic subgroup.
ARPA-H’s THRIVE program is attempting to replace the traditional one-product, one-disease and one-trial approach with modular genetic-medicine platforms. The agency expects participating teams to develop multiple products that can draw on shared biodistribution, toxicology, manufacturing and clinical information. It has committed up to $160 million across the broader five-year THRIVE program, with individual awards dependent on teams meeting accelerated technical and clinical milestones.
For PERC, that could mean using TfR1 CapX as a common delivery vehicle while changing the disease-specific editing components for different mutations. Manufacturing support will be provided by Viralgen, an adeno-associated virus contract development and manufacturing organisation. The consortium also brings together hospitals, animal-model specialists, regulatory organisations and patient advocacy groups, reflecting the fact that rare-disease development failures frequently arise outside the laboratory, particularly in patient identification, manufacturing, trial recruitment and long-term follow-up.
The shared model could improve the commercial feasibility of therapies that would be difficult to justify as standalone biotechnology programs. Common processes may reduce duplicated development work, provide more predictable manufacturing requirements and create a clearer route for expanding from an initial disease into additional genetic disorders.
The economic case remains unproven, however. Platform efficiencies will depend on how much information regulators permit developers to carry from one product to another and whether disease-specific modifications remain sufficiently comparable. Small patient populations will also complicate trial design, endpoint selection, treatment-centre economics and long-term evidence generation.
Which regulatory and manufacturing hurdles could slow the umbrella trial model?
ARPA-H has set an aggressive timetable. During the first year, THRIVE teams are expected to demonstrate platforms capable of producing multiple drug candidates with common biodistribution and toxicology characteristics. By the third year, teams are expected to have begun first-in-human studies accommodating several products and disease phenotypes, while the fifth-year objective involves expanding umbrella Investigational New Drug applications and clinical trials to additional therapies. These are program milestones rather than confirmed clinical outcomes.
The regulatory environment is becoming more receptive to the use of platform knowledge. Draft guidance issued by the United States Food and Drug Administration in June 2026 describes how sponsors may use prior public and platform information, including manufacturing, nonclinical and clinical knowledge, to reduce unnecessary duplication across genome-editing programs. That direction is closely aligned with THRIVE’s underlying model, although the guidance remains draft policy and does not remove the need for product-specific evidence.
Genome-editing products must still address unintended editing, off-target activity, genomic integrity, product quality, nonclinical safety and clinical-trial design. The Food and Drug Administration’s 2024 final guidance identifies product design, manufacturing, testing and nonclinical assessment as core components of an Investigational New Drug submission, while April 2026 draft guidance provides more detailed recommendations for sequencing-based assessment of off-target editing.
Apertura and the consortium will also have to characterise TfR1 CapX biodistribution beyond the intended brain and spinal-cord targets. Receptor-directed transport may improve central nervous system exposure, but regulators will need data showing where the vector and editing machinery travel, how long they persist and whether clinically relevant editing occurs in unintended tissues.
Adeno-associated virus immunity represents another implementation challenge. The Food and Drug Administration has noted that immune responses to AAV capsids can neutralise vectors, limit transduction and contribute to immune-mediated toxicity. Such issues may affect patient eligibility, dosing strategies and the feasibility of repeat treatment, particularly when a program seeks to use the same capsid across several diseases.
Manufacturing comparability will be equally important. A shared platform is most valuable when production methods remain stable as disease-specific payloads change. Viralgen will therefore need to demonstrate reproducible vector potency, purity, identity and yield across multiple editing products rather than producing a single successful research batch.
What does the ARPA-H consortium role mean for Apertura Gene Therapy?
Apertura is privately held, so there is no public share-price reaction or listed-company sentiment to evaluate. The strategic value of the announcement lies instead in external adoption of its capsid platform, access to a major government-backed development network and the possibility that PERC will generate regulatory and manufacturing knowledge applicable to other TfR1 CapX programs.
The company has been expanding TfR1 CapX through licensing and research collaborations. In July 2026, Apertura entered a Cooperative Research and Development Agreement with two National Institutes of Health institutes to evaluate an investigational intravenous gene therapy for Niemann-Pick disease type C1. It has also formed a collaboration with the TSC Alliance to investigate TfR1 CapX-based programs for tuberous sclerosis complex. Both initiatives remain in preclinical development.
Apertura has said several partner programs using its capsids are expected to enter clinical trials within the next 12 months. That expectation could provide the first meaningful human evidence for the platform, but it is a company projection rather than a confirmed regulatory or clinical milestone. The identity, indication and final trial timing of each program will matter when assessing whether the capsid is progressing from a widely licensed experimental tool into a clinically usable delivery platform.
Participation in PERC may improve Apertura’s credibility with prospective partners because the capsid has been selected for a consortium involving the Broad Institute, specialist children’s hospitals, Viralgen and rare-disease advocacy organisations. It does not yet validate clinical safety, editing efficiency or commercial scalability, and it does not guarantee that PERC will select TfR1 CapX for every product ultimately advanced into human testing.
The decisive milestones will be the selection of clinical candidates, completion of manufacturing and toxicology packages, evidence that TfR1 CapX achieves predictable central nervous system exposure, regulatory acceptance of shared platform data and initiation of the first human trial. The program will become materially important to patients only when the consortium shows that its reusable infrastructure can convert encouraging mouse studies into carefully controlled treatments for children with rare neurological diseases.
